Milestone Pharmaceuticals Inc. - Common Shares (MIST) Covered Calls
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on cardiovascular medicines. Its lead product, CARDAMYST (etripamil), is a self-administered nasal spray for the rapid treatment of paroxysmal supraventricular tachycardia (PSVT). The company aims to provide fast-acting, at-home solutions for acute cardiac episodes, reducing the need for emergency room visits. Milestone is also evaluating etripamil for other conditions, including atrial fibrillation.
You can sell covered calls on Milestone Pharmaceuticals Inc. - Common Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for MIST (prices last updated Thu 11:15 AM ET):
| Milestone Pharmaceuticals Inc. - Common Shares (MIST) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 1.94 | -0.06 | 1.94 | 1.95 | 697K | - | 0.2 |
| Covered Calls For Milestone Pharmaceuticals Inc. - Common Shares (MIST) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| May 15 | 2 | 0.15 | 1.80 | 8.3% | 132% | |
| Jun 18 | 2 | 0.25 | 1.70 | 14.7% | 94.1% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Milestone Pharmaceuticals Inc. is dedicated to improving the lives of patients with episodic cardiovascular conditions through the development of self-administered, rapid-response therapies. Headquartered in Montreal, the company operates with a specialized focus on calcium channel blockers delivered via nasal spray. This innovative delivery method is designed to provide hospital-grade efficacy in a convenient, portable format, allowing patients to manage acute cardiac episodes whenever and wherever they occur.
Core Business and Products
The company flagship product is CARDAMYST (etripamil) nasal spray, which recently received FDA approval for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. Etripamil is a potent, short-acting calcium channel blocker that enters the bloodstream quickly through the nasal mucosa, offering a rapid onset of action. Beyond PSVT, Milestone is advancing a clinical pipeline to evaluate etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR). The company commercial strategy involves direct sales in the U.S. and strategic partnerships, such as its collaboration with Corxel Pharmaceuticals, to reach international markets.
Competitive Landscape
- BioMarin Pharmaceutical Inc. is a competitor in the broader specialty biopharma space, focusing on genetic and rare conditions, which competes for institutional investment and specialized talent.
- Allogene Therapeutics, Inc. competes in the advanced therapy sector, specifically within clinical-stage biotechnology, vying for market attention and venture-linked growth capital.
- Prime Medicine, Inc. is an innovator in gene editing and biotechnology that competes with specialized drug developers for clinical research resources and strategic licensing opportunities.
- Ocugen, Inc. focuses on discovering and developing gene therapies and vaccines for under-served diseases, representing competition in the small-cap biotechnology and regulatory approval landscape.
- Blueprint Medicines Corporation is a global precision therapy company that competes in the development of targeted medicines for specific molecular drivers of disease, including cardiovascular indications.
Strategic Outlook and Innovation
The strategic focus for Milestone Pharmaceuticals in 2026 is the broad commercial launch of CARDAMYST and its inclusion in major insurance formularies, such as Express Scripts. The company is actively generating real-world evidence through registries like RESET-PSVT to demonstrate the long-term safety and utility of etripamil in everyday settings. By proving the value of self-management for cardiac episodes, Milestone aims to reduce the burden on emergency departments and lower overall healthcare costs, positioning itself as a leader in "at-home" acute care.
Innovation at the company is centered on expanding the therapeutic applications of its nasal spray platform. Ongoing research into AFib-RVR represents a significant market expansion opportunity, as the company seeks to address a much larger patient population than PSVT alone. Additionally, Milestone is exploring the development of next-generation delivery devices to further simplify the administration process for patients. These scientific and commercial efforts are supported by a lean operating model designed to focus capital on late-stage clinical development and market penetration in the cardiovascular space.
| Top 10 Open Interest For May 15 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | TLT covered calls | 1. | INTC covered calls | |
| 2. | SLV covered calls | 7. | HYG covered calls | 2. | NVTS covered calls | |
| 3. | IBIT covered calls | 8. | QQQ covered calls | 3. | CRML covered calls | |
| 4. | GLD covered calls | 9. | KWEB covered calls | 4. | POET covered calls | |
| 5. | SPY covered calls | 10. | EEM covered calls | 5. | CIFR covered calls | |
Want more examples? MIRM Covered Calls | MITK Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
